These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18809819)

  • 41. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
    Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
    N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.
    Vijayaraghavan A; Efrusy MB; Mazonson PD; Ebrahim O; Sanne IM; Santas CC
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):91-100. PubMed ID: 17621241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of disease stage on direct medical costs of HIV management: a review of the international literature.
    Levy A; Johnston K; Annemans L; Tramarin A; Montaner J
    Pharmacoeconomics; 2010; 28 Suppl 1():35-47. PubMed ID: 21182342
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.
    Phillips AN; Pillay D; Miners AH; Bennett DE; Gilks CF; Lundgren JD
    Lancet; 2008 Apr; 371(9622):1443-51. PubMed ID: 18440426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
    Medina Lara A; Kigozi J; Amurwon J; Muchabaiwa L; Nyanzi Wakaholi B; Mujica Mota RE; Walker AS; Kasirye R; Ssali F; Reid A; Grosskurth H; Babiker AG; Kityo C; Katabira E; Munderi P; Mugyenyi P; Hakim J; Darbyshire J; Gibb DM; Gilks CF;
    PLoS One; 2012; 7(4):e33672. PubMed ID: 22545079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contemporary costs of HIV healthcare in the HAART era.
    Gebo KA; Fleishman JA; Conviser R; Hellinger J; Hellinger FJ; Josephs JS; Keiser P; Gaist P; Moore RD;
    AIDS; 2010 Nov; 24(17):2705-15. PubMed ID: 20859193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.
    Freedberg KA; Kumarasamy N; Borre ED; Ross EL; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP
    AIDS Res Hum Retroviruses; 2018 Jun; 34(6):486-497. PubMed ID: 29620932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda.
    Sempa J; Ssennono M; Kuznik A; Lamorde M; Sowinski S; Semeere A; Hermans S; Castelnuovo B; Manabe YC
    BMC Public Health; 2012 Sep; 12():736. PubMed ID: 22943068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis.
    Kimaro GD; Guinness L; Shiri T; Kivuyo S; Chanda D; Bottomley C; Chen T; Kahwa A; Hawkins N; Mwaba P; Mfinanga SG; Harrison TS; Jaffar S; Niessen LW
    Clin Infect Dis; 2020 Apr; 70(8):1652-1657. PubMed ID: 31149704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Munakata J; Benner JS; Becker S; Dezii CM; Hazard EH; Tierce JC
    Med Care; 2006 Oct; 44(10):893-9. PubMed ID: 17001259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Costs and benefits to the mother of antenatal HIV testing: estimates from simulation modelling.
    Gibb DM; Ades AE; Gupta R; Sculpher MJ
    AIDS; 1999 Aug; 13(12):1569-76. PubMed ID: 10465082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How Will New Guidelines Affect CD4 Testing in Veterans With HIV?
    Barnett PG; Schmitt SK; Yu W; Goetz MB; Ohl ME; Asch SM
    Clin Infect Dis; 2016 Jul; 63(1):96-100. PubMed ID: 27045125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Clinical Impact and Cost-Effectiveness of Clinic-Based Cognitive Behavioral Therapy for People With HIV, Depression, and Virologic Failure in South Africa.
    Gandhi AR; Hyle EP; Scott JA; Lee JS; Shebl FM; Joska JA; Andersen LS; O'Cleirigh C; Safren SA; Freedberg KA
    J Acquir Immune Defic Syndr; 2023 Aug; 93(4):333-342. PubMed ID: 37079899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.
    Kimmel AD; Weinstein MC; Anglaret X; Goldie SJ; Losina E; Yazdanpanah Y; Messou E; Cotich KL; Walensky RP; Freedberg KA;
    J Acquir Immune Defic Syndr; 2010 Jul; 54(3):258-68. PubMed ID: 20404739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.